• Explore /
  • Poster
  • / A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.

Abstract Poster

Authors

null

Karim Fizazi

Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Karim Fizazi , Albertas Ulys , Lisa Sengeløv , Mette Moe , Sylvain Ladoire , Antoine Thiery- Vuillemin , Aude Flechon , Roberto Sabbatini , Joaquim Bellmunt , Miguel Angel Climent , Simon Chowdhury , Herlinde Dumez , Michaela Matouskova , Nicolas Penel , Sigita Liutkauskiene , Lech Stachurski , Cora N. Sternberg , Frederique Baton , Nathalie Germann , Gedske Daugaard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01732549

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 201)

DOI

10.1200/jco.2016.34.2_suppl.201

Abstract #

201

Poster Bd #

H16

Abstract Disclosures

Similar Posters

First Author: Karim Fizazi

First Author: Orazio Caffo

First Author: Orazio Caffo

First Author: Richard Cathomas